Relationship between platelet parameters and disease severity and coagulpathy in covid 19

Year 2022, , 48 - 57, 29.04.2022

Sertaş Erarslan , Türkan Paşalı Kilit , Sevil Alkan Çeviker , Hasan Hüseyin Gümüşçü Mustafa Akıncı Aynur Gülcan

https://doi.org/10.56016/dahudermj.1093868

Cited By: 1

Abstract

Objectives: Coagulopathy plays an important role in the clinical course of Covid-19 disease. The aim of our study is to examine the factors affecting the severity of this disease and to examine whether there is a relationship between platelet parameters and disease severity and coagulopathy markers.
Methods: The study was planned single-center, retrospective, and cross-sectional. 189 patients diagnosed with Covid-19 were admitted to the Internal Medicine Department. Patients were divided into 3 clinical categories according to the severity of the disease. The relationship between mean platelet volume and other platelet parameters, and disease severity and coagulopathy parameters were statistically analyzed.
Results: The study included 189 patients.182 of whom were discharged and 7 of whom died. The average age of the patients was 54.13 ± 14.21. D-Dimer levels were compared between the groups and were found to be significantly higher in cases of severe pneumonia. The group with severe pneumonia group had a higher PDW level than other groups. MPV was detected over 10 fl in the severe pneumonia group, but no statistically significant difference was found with the other groups. PT and INR levels are higher in patients with upper respiratory tract infection (URTI) compared to patients with mild to moderate pneumonia. APTT levels were found to be higher in patients with URTI than in patients with severe pneumonia.
Conclusion: In our study, PDW height and MPV height were determined from the findings showing platelet activation in patients with severe pneumonia. If an increase in these parameters is detected in patients diagnosed with the Covid 19 disease, close follow-up should be performed in terms of the development of complications.

Keywords

covid19, platelet, platelet parameters

References

• Chan JF, Kok KH, Zhu Z, Chu H, To KK, Yuan S, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect 2020;9: 221.36.
• C. Calisher, D. Carroll, R. Colwell, R.B. Corley, P. Daszak, C. Drosten, L. Enjuanes, J. Farrar, H. Field, J. Golding. Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19, The Lancet, 395 (2020) e42-e43.
• J. P. Metlay, G. W. Waterer, A. C. Long, et al. Diagnosis and treatment of adults with community-acquired pneumonia: An official clinical practice guideline of the American Thoracic Society and Infectious Disease Society of America, Am. J. Respir Crit Care Med 200(2019): e45–e67.
• Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2(ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 2020;46(4):586-590.
• Han H, Yang L, Liu R, at al. Prominent changes in blood coagulation of patient with SARS-Cov-2 infection. Clin Chem Lab Med 2020.
• Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720.
• Von Hundelshausen P, Weber C. Platelets as immune cells. Bridging inflammation and cardiovascular disaese. Circ Res 2007;100: 27-40.
• Bath PM, Butterworth RJ. Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis 1996 Mar;7(2):157- 161.
• Van der Lelie J, Von dem Borne AEG. Platelet volume analysis for differential diagnosis of thrombocytosis. J Clin Pathol 1986;39: 129.
• Tavil Y, Sen N, Yazici H, et al. Coronary heart disease is associated with mean platelet volume in type 2 diabetic patients. Platelets 2010;21(5):368-372.
• Chu SG, Becker RC, Berger PB, et al. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J ThrombHaemost 2010 Jan;8(1):148-156.
• Zhang S, Cui Y, et al. Use of Platelet Indices for Determining Illness Severity and Predicting Prognosis in Critically Ill Patients. Chin Med J (Engl). 2015 Aug 5; 128(15): 2012–2018.
• Steiropoulos P, Papanas N, Nena E, et al. Mean platelet volume and platelet distribution with in patients with chronic obstructive pulmonary disease: The role of comorbidities. Angiology 2013; 64:535 9.
• Kirbas Ö, Kurmus Ö, Köseoglu C, Duran Karaduman B, Saatçi Yasar A, Alemdar R, et al. Association between admission mean platelet volume and ST segment resolution after thrombolytic therapy for acute myocardial infarction. Anadolu KardiyolDerg 2014; 14:728 32.
• Brogly N, Devos P, Boussekey N, Georges H, Chiche A, Leroy O. Impact of thrombocytopenia on outcome of patients admitted to ICU for severe community-acquired pneumonia. J Infect 2007; 55:136–140.
• Wong RS, Wu A, To KF, et al. Hematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis. BMJ 2003; 326:1358–1362.
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020.
• Liu Y, Sun W, et al. Association between platelet parameters and mortality in coronavirus disease 2019: Retrospective cohort study. Journal Platelets. 2020; 31(4): 490-6.
• Lippi G, Plebani M, Michael Henry B. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clin Chim Acta 2020.
• Cannegieter SC, Klok FA. COVID-19 associated coagulopathy and thromboembolic disease: Commentary on an interim expert guidance. Res PractThrombHaemost 2020 April 20.
• Zhang L, Long Y, Xiao H, at al. Use of D -dimer in oral anticoagulation therapy. International Journal of Laboratory Hematology. 2018;40(5):503 –7.
• Ferrari D, Motta A, Strollo M, Banfi G, Locatelli M. Routine blood tests as a potential diagnostic tool for COVID-19. Clin Chem Lab Med. 2020 Apr 16.
• Li CX, Wu B, Luo F, Zhang N. Clinical Study and CT Findings of a Familial Cluster of Pneumonia with Coronavirus Disease 2019 (COVID-19). Sichuan Da XueXue Bao Yi Xue Ban. 2020;51(2):155-158.
• Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J ThrombHaemost. 2020;18(4):844 –847.
• Zhang L, Yan X, Fan Q, et al. D -dimer levels on admission to predict in -hospital mortality in patients with Covid -19. J ThrombHaemost. 2020 Apr 19. 18(6): 1324-29.
• Muhammed Kermali, Raveena Kaur Khalsa, Kiran Pillai, at al. The role of biomarkers in diagnosis of COVID-19 – A systematic review. Life Sciences. 2020.
• Han H, Yang L, et al. Prominent changes in blood coagulation of patients with Sars-CoV2 infection. Clin Chem Lab Med. 2020. Jun 25;58(7):1116-20.
• Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID -19 in Wuhan, China. Clin Infect Dis. 2020 Mar 12; 9.
• Liu F, Li L, Xu M, et al. Prognostic level of interleukin -6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol. 2020 Apr 14;127: 104370.